Cardioprotective effects of remimazolam in elderly hypertensive patients undergoing gastrointestinal tumor surgery: A randomized controlled trial

Table 8 Comparison of baseline characteristics between non-myocardial injury after non-cardiac surgery and myocardial injury after non-cardiac surgery patients, mean ± SD/n (%)

Item	Non-MINS group (n = 56)	MINS group (n = 24)	χ2/t value	P value
Sex			1.878	0.171
Male	33 (58.93)	18 (75.00)
Female	23 (41.07)	6 (25.00)
Age (years)	71.96 ± 7.45	73.29 ± 7.74	-0.722	0.472
ASA classification			2.018	0.155
II	18 (32.14)	4 (16.67)
III	38 (67.86)	20 (83.33)
Height (cm)	165.27 ± 6.66	165.54 ± 6.98	-0.166	0.869
Weight (kg)	64.79 ± 9.57	64.17 ± 10.99	0.254	0.801
BMI (kg/m2)	23.70 ± 3.16	23.21 ± 3.06	0.634	0.528
Tumor type			13.582	0.004
Colon cancer	28 (50.00)	3 (12.50)
Rectal cancer	10 (17.86)	11 (45.83)
Gastric cancer	18 (32.14)	9 (37.50)
Gastrointestinal stromal tumor	0 (0.00)	1 (4.17)
Comorbidities
Cerebral infarction	10 (17.86)	1 (4.17)	1.626	0.202
Diabetes mellitus	10 (17.86)	6 (25.00)	0.182	0.669
Coronary heart disease	2 (3.57)	1 (4.17)	0.000	1.000
Others	5 (8.93)	3 (12.50)	0.007	0.935
Anesthesia strategy			8.571	0.003
Conventional general anesthesia (P group)	22 (39.29)	18 (75.00)
General anesthesia + remimazolam (R group)	34 (60.71)	6 (25.00)

MINS: Myocardial injury after non-cardiac surgery; P group: Control group (propofol-based intravenous general anesthesia); R group: Experimental group (remimazolam-based intravenous general anesthesia); ASA: American Society of Anesthesiologists; BMI: Body mass index.